Selective Estrogen Receptor Down-Regulator and Selective Estrogen Receptor Modulators Differentially Regulate Lactotroph Proliferation
暂无分享,去创建一个
S. Kansra | N. Ben-Jonathan | Shenglin Chen | M. Bangaru | Leighton Sneade | Joseph A Dunckley | M. L. Bangaru | Joseph A. Dunckley
[1] F. Collins,et al. Mouse Embryo Fibroblasts Lacking the Tumor Suppressor Menin Show Altered Expression of Extracellular Matrix Protein Genes , 2007, Molecular Cancer Research.
[2] S. Kansra,et al. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release , 2005, Molecular and Cellular Endocrinology.
[3] D. Sarkar,et al. Distinct signaling pathways mediate stimulation of cell cycle progression and prevention of apoptotic cell death by estrogen in rat pituitary tumor PR1 cells. , 2003, Molecular biology of the cell.
[4] G. Leclercq,et al. Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[5] B. Katzenellenbogen,et al. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression , 2003, Molecular and Cellular Endocrinology.
[6] S. Belcher,et al. Estrogens and ICI182,780 (Faslodex) Modulate Mitosis and Cell Death in Immature Cerebellar Neurons via Rapid Activation of p44/p42 Mitogen-Activated Protein Kinase , 2003, The Journal of Neuroscience.
[7] B. Staels,et al. Peroxisome Proliferator-activated Receptor α (PPARα) Turnover by the Ubiquitin-Proteasome System Controls the Ligand-induced Expression Level of Its Target Genes* , 2002, The Journal of Biological Chemistry.
[8] S. Melmed,et al. Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells. , 2002, The Journal of endocrinology.
[9] B. Katzenellenbogen,et al. Antagonists Selective for Estrogen Receptor α. , 2002, Endocrinology.
[10] Li Zhao,et al. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[11] E. Alarid,et al. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. , 1999, Molecular endocrinology.
[12] O. Jänne,et al. Ubc9 Interacts with the Androgen Receptor and Activates Receptor-dependent Transcription* , 1999, The Journal of Biological Chemistry.
[13] M. Tsai,et al. The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily , 1999, Molecular and Cellular Biology.
[14] J. Polman,et al. ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .
[15] M. Imhof,et al. Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors , 1996, Molecular and cellular biology.
[16] C. Newton. Estrogen receptor blockade by the pure antiestrogen, ZM 182780, induces death of pituitary tumour cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[17] R. Thampan,et al. Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. , 1995, Biochemical and biophysical research communications.
[18] D. Moore,et al. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator , 1995, Nature.
[19] A. Gutierrez-Hartmann,et al. Activation of the prolactin promoter in transfected GH3 cells by posterior pituitary cells. , 1994, Endocrinology.
[20] M. Parker,et al. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. , 1993, Journal of cell science.
[21] M. Parker,et al. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[22] A. Wakeling,et al. A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.
[23] S. Fawell,et al. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[24] E. Jensen,et al. Estrogen-binding substances of target tissues. , 1969, Science.
[25] E. Jensen,et al. Estrogen-binding substances of target tissues. , 1967, Steroids.
[26] B. Katzenellenbogen,et al. Antagonists selective for estrogen receptor alpha. , 2002, Endocrinology.
[27] B. Staels,et al. Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. , 2002, The Journal of biological chemistry.
[28] B. O’Malley,et al. FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. , 2001, Nature cell biology.
[29] B. O’Malley,et al. FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent , 2000, Nature Cell Biology.
[30] J. Gustafsson,et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.
[31] J. Polman,et al. ER beta: identification and characterization of a novel human estrogen receptor. , 1996, FEBS letters.